Literature DB >> 16163369

Surfactant administration by transient intubation in infants 29 to 35 weeks' gestation with respiratory distress syndrome decreases the likelihood of later mechanical ventilation: a randomized controlled trial.

Ann Reininger1, Rubia Khalak, James W Kendig, Rita M Ryan, Timothy P Stevens, Linda Reubens, Carl T D'Angio.   

Abstract

OBJECTIVE: To assess, among premature infants with early respiratory distress syndrome (RDS), the effect of one dose of intratracheally administered surfactant followed by extubation to nasal continuous positive airway pressure (NCPAP) on subsequent mechanical ventilation (MV), when compared with NCPAP alone. STUDY
DESIGN: Randomized, blinded trial in infants 29 to 35 weeks' gestation with mild-to-moderate RDS requiring supplemental oxygen and NCPAP. Infants were randomized to intubation, surfactant treatment, and immediate extubation (surfactant group N=52), or to no intervention (control group N=53). All infants were subsequently managed with NCPAP.
RESULTS: Need for later MV was 70% in the control group and 50% in the surfactant group. Surfactant group subjects had lower inspired oxygen fraction (FiO(2)) after study intervention and were less likely to require subsequent surfactant. Overall surfactant use, duration of O(2) therapy, length of stay, and bronchopulmonary dysplasia were unaffected.
CONCLUSION: Among premature infants with mild-to-moderate RDS, transient intubation for surfactant administration reduces later MV. Journal of Perinatology (2005) 25, 703-708. doi:10.1038/sj.jp.7211381; published online 15 September 2005.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16163369     DOI: 10.1038/sj.jp.7211381

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  25 in total

1.  A new clinical respiratory distress score for surfactant therapy in preterm infants with respiratory distress.

Authors:  Debasish Nanda; Sushma Nangia; Anu Thukral; C P Yadav
Journal:  Eur J Pediatr       Date:  2019-12-18       Impact factor: 3.183

Review 2.  Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome.

Authors:  Felicia L Bahadue; Roger Soll
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14

Review 3.  Surfactant therapy: the current practice and the future trends.

Authors:  Khalid Altirkawi
Journal:  Sudan J Paediatr       Date:  2013

Review 4.  Intra-amniotic surfactant for women at risk of preterm birth for preventing respiratory distress in newborns.

Authors:  Mohamed E Abdel-Latif; David A Osborn; Daniel Challis
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

5.  Role of microRNA-150 and glycoprotein nonmetastatic melanoma protein B in angiogenesis during hyperoxia-induced neonatal lung injury.

Authors:  Telugu Narasaraju; Dhananjay Shukla; Sunil More; Chaoqun Huang; Li Zhang; Xiao Xiao; Lin Liu
Journal:  Am J Respir Cell Mol Biol       Date:  2015-02       Impact factor: 6.914

Review 6.  Use of CPAP and surfactant therapy in newborns with respiratory distress syndrome.

Authors:  Srinivas Murki; Ashok Deorari; Dharmapuri Vidyasagar
Journal:  Indian J Pediatr       Date:  2014-04-12       Impact factor: 1.967

7.  Prevention of bronchopulmonary dysplasia.

Authors:  Matthew M Laughon; P Brian Smith; Carl Bose
Journal:  Semin Fetal Neonatal Med       Date:  2009-09-06       Impact factor: 3.926

Review 8.  What is new in ventilation strategies for the neonate?

Authors:  Anne Greenough; Atul Sharma
Journal:  Eur J Pediatr       Date:  2007-06-02       Impact factor: 3.183

9.  Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome.

Authors:  Mohamed E Abdel-Latif; Peter G Davis; Kevin I Wheeler; Antonio G De Paoli; Peter A Dargaville
Journal:  Cochrane Database Syst Rev       Date:  2021-05-10

10.  Trends in survival among extremely-low-birth-weight infants (less than 1000 g) without significant bronchopulmonary dysplasia.

Authors:  Francesc Botet; Josep Figueras-Aloy; Xavier Miracle-Echegoyen; José Manuel Rodríguez-Miguélez; Maria Dolors Salvia-Roiges; Xavier Carbonell-Estrany
Journal:  BMC Pediatr       Date:  2012-06-08       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.